Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2022
- Primary completion
- Jan 2027
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, randomised, open-label trial of PIT565 in B-cell non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia (B-ALL) (5 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 35 days, Adverse Events and Serious Adverse Events at 21 months and 3 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
PIT565
03
Conditions
B-cell non-Hodgkin lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05397496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397496.